Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.54 |
| ▸ | NOS2 | P35228 | 6/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052799 | 0.87 | SLC6A2 (0.56) | SLC6A4SLC6A2NOS2CYP2D6SLC6A3 | |
| SCHEMBL14607925 | 0.84 | SLC7A5 (0.51) | SLC6A4SLC6A2NOS2CYP2D6SLC6A3 | |
| SCHEMBL8496227 | 0.84 | SLC7A5 (0.51) | SLC6A4SLC6A2NOS2CYP2D6SLC6A3 | |
| SCHEMBL14607958 | 0.84 | SLC7A5 (0.51) | SLC6A4SLC6A2NOS2CYP2D6SLC6A3 | |
| SCHEMBL6721958 | 0.83 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7053107 | 0.83 | SLC6A4 (0.77) | SLC6A4SLC6A2NOS2CYP2D6SLC6A3 | |
| SCHEMBL5431801 | 0.82 | SLC6A4 (0.46) | SLC6A4SLC6A2NOS2CYP2D6SLC6A3 | |
| Oxalic Acid SCHEMBL7317717 | 0.81 | SLC6A2 (0.60) | SLC6A4SLC6A2NOS2CYP2D6SLC6A3 | |
| SCHEMBL11236293 | 0.80 | NOS2 (0.54) | SLC6A4SLC6A2NOS2CYP2D6SLC6A3 | |
| SCHEMBL7053112 | 0.80 | SLC6A4 (0.70) | SLC6A4SLC6A2CYP2D6SLC6A3SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0831799-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMA INC (US) | 2003-05-02 | — | — | EP | claimed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | claimed |
| US-7217696-B2 | Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof | A & D BIOSCIENCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050130908-A1 | Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof | HOLICK MICHAEL F (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1487460-A2 | GLYCURONAMIDES, GLYCOSIDES AND ORTHOESTER GLYCOSIDES OF FLUOXETINE, ANALOGS AND USES THEREOF | A & D Bioscience, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003073988-A2 | GLYCURONAMIDES, GLYCOSIDES AND ORTHOESTER GLYCOSIDES OF FLUOXETINE, ANALOGS AND USES THEREOF | A & D BIOSCIENCE, INC. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130908-A1 | Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof | PYGB, GBA3, GAA | SLC6A4 121/4885SLC6A2 130/4885NOS2 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.